A recent study demonstrates that the monoclonal antibody-based vaccine L9LS is safe for children aged 6 to 10 and significantly reduces the risk of malaria infection and clinical symptoms by 70% and 77%, respectively.
One injected dose of an experimental malaria monoclonal antibody was 77% effective against malaria disease in children in Mali during the country’s six-month malaria season, according to the results of a mid-stage clinical trial. The trial assessed an investigational monoclonal antibody developed by scientists at the National Institutes of Health (NIH), and results appear in <em>The New England Journal of Medicine</em>.
Experimental malaria monoclonal antibody protective in Malian children medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.
U S FDA Approves Subcutaneous Administration of Takeda s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn s Disease streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.